Robert Daniel Van Horn

机构：Eli Lilly (United States) · ORCID：0000-0001-6685-8120

发表论文 95 篇 · 总被引 1673 次 · h-index 19

代表论文

Porcine intestinal organoids cultured in an organ-on-a-chip microphysiological system (2025 · Biochemistry and Biophysics Reports · 被引 3)
Aggregated proinsulin in pancreatic β-cells is degraded by the autophagy pathway (2025 · Journal of Biological Chemistry · 被引 2)
Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models (2026 · Nature Communications)
Data from The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation (2023)
Data from A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models (2023)
Data from Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy (2023)